FDA Sets Advisory Meeting for Abecma in Supplemental Multiple Myeloma Indication.

The article highlights Food and Drug Administration advisory meeting on March 15, 2024, to review Abecma's efficacy in earlier lines of treatment for relapsed or refractory multiple myeloma. Topics include the meeting's focus on overall survival data from the KarMMa-3 study, Abecma's performance in comparison to standard regimens, and its adverse event profile.